Genetic Issues in Patients with Breast Cancer

Fossland, Victoria Sahadevan; Stroop, Jennifer; Schwartz, R C; Kurtzman, Scott H.

doi:10.1016/j.soc.2008.08.008

Cited by 6 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5] The number of effective treatments for breast cancer is on the rise and breast cancer is often regarded as one of the most chemoresponsive tumors. However, interindividual variations in therapeutic response and drug toxicity are important problems in breast cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

et al. 2009

View full text Add to dashboard Cite

P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P ¼ 0.024, 0.014, 0.006, respectively, w 2 -test or Fisher's exact test). We also found significantly higher (P ¼ 0.019, w 2 -test) T allele frequency in breast cancer patients (n ¼ 221) than in controls (n ¼ 113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n ¼ 38; P ¼ 0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n ¼ 102; P ¼ 0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.

show abstract